These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 32043980)

  • 1. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial.
    Rullier E; Vendrely V; Asselineau J; Rouanet P; Tuech JJ; Valverde A; de Chaisemartin C; Rivoire M; Trilling B; Jafari M; Portier G; Meunier B; Sieleznieff I; Bertrand M; Marchal F; Dubois A; Pocard M; Rullier A; Smith D; Frulio N; Frison E; Denost Q
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):465-474. PubMed ID: 32043980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.
    Rullier E; Rouanet P; Tuech JJ; Valverde A; Lelong B; Rivoire M; Faucheron JL; Jafari M; Portier G; Meunier B; Sileznieff I; Prudhomme M; Marchal F; Pocard M; Pezet D; Rullier A; Vendrely V; Denost Q; Asselineau J; Doussau A
    Lancet; 2017 Jul; 390(10093):469-479. PubMed ID: 28601342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
    Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
    Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.
    Bach SP; Gilbert A; Brock K; Korsgen S; Geh I; Hill J; Gill T; Hainsworth P; Tutton MG; Khan J; Robinson J; Steward M; Cunningham C; Levy B; Beveridge A; Handley K; Kaur M; Marchevsky N; Magill L; Russell A; Quirke P; West NP; Sebag-Montefiore D;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):92-105. PubMed ID: 33308452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial.
    Park JW; Kang SB; Hao J; Lim SB; Choi HS; Kim DW; Chang HJ; Kim DY; Jung KH; Kim TY; Kang GH; Chie EK; Kim SY; Sohn DK; Kim JS; Lee HS; Kim JH; Jeong SY; Oh JH
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):569-577. PubMed ID: 33894918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
    Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.
    Fujita S; Akasu T; Mizusawa J; Saito N; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Shiozawa M; Yamaguchi T; Moriya Y;
    Lancet Oncol; 2012 Jun; 13(6):616-21. PubMed ID: 22591948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer.
    Akiyoshi T; Toda S; Tominaga T; Oba K; Tomizawa K; Hanaoka Y; Nagasaki T; Konishi T; Matoba S; Fukunaga Y; Ueno M; Kuroyanagi H
    BJS Open; 2019 Dec; 3(6):822-829. PubMed ID: 31832589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial.
    Feng Q; Yuan W; Li T; Tang B; Jia B; Zhou Y; Zhang W; Zhao R; Zhang C; Cheng L; Zhang X; Liang F; He G; Wei Y; Xu J;
    Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):991-1004. PubMed ID: 36087608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
    Hofheinz RD; Wenz F; Post S; Matzdorff A; Laechelt S; Hartmann JT; Müller L; Link H; Moehler M; Kettner E; Fritz E; Hieber U; Lindemann HW; Grunewald M; Kremers S; Constantin C; Hipp M; Hartung G; Gencer D; Kienle P; Burkholder I; Hochhaus A
    Lancet Oncol; 2012 Jun; 13(6):579-88. PubMed ID: 22503032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for local recurrence in patients with rectal cancer submitted to neoadjuvant chemoradiotherapy and total mesorectal excision.
    Nahas CSR; Nahas SC; Marques CFS; Ribeiro Junior U; Bustamante-Lopez L; Cotti GC; Imperiale AR; Pinto RA; Cecconello I
    Clinics (Sao Paulo); 2024; 79():100464. PubMed ID: 39126876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
    Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
    World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.
    Park IJ; You YN; Skibber JM; Rodriguez-Bigas MA; Feig B; Nguyen S; Hu CY; Chang GJ
    Dis Colon Rectum; 2013 Feb; 56(2):135-41. PubMed ID: 23303140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial.
    Gerard JP; Barbet N; Schiappa R; Magné N; Martel I; Mineur L; Deberne M; Zilli T; Dhadda A; Myint AS;
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):356-367. PubMed ID: 36801007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of survival and functional outcomes after total mesorectal excision with or without lateral pelvic lymph node dissection in rectal cancer surgery.
    Hajibandeh S; Hajibandeh S; Matthews J; Palmer L; Maw A
    Surgery; 2020 Sep; 168(3):486-496. PubMed ID: 32620303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study.
    Stijns RCH; de Graaf EJR; Punt CJA; Nagtegaal ID; Nuyttens JJME; van Meerten E; Tanis PJ; de Hingh IHJT; van der Schelling GP; Acherman Y; Leijtens JWA; Bremers AJA; Beets GL; Hoff C; Verhoef C; Marijnen CAM; de Wilt JHW;
    JAMA Surg; 2019 Jan; 154(1):47-54. PubMed ID: 30304338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
    Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
    Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy in Clinical Stage T3N0 Low and Mid Rectal Cancer.
    Lin Y; Lin H; Xu Z; Zhou S; Chi P
    J Invest Surg; 2019 Nov; 32(7):679-687. PubMed ID: 30215538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 29.